

29 October 2024

## Breast Cancer Treatments

**Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:**

- **Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) - <5**
- **Abemaciclib + Fulvestrant - 10**
- **Alpelisib + Fulvestrant - 5**
- **Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide - 7**
- **Aromatase Inhibitor as a single agent - <5**
- **Atezolizumab - <5**
- **Capecitabine as a single agent - 45**
- **Carboplatin + Paclitaxel - <5**
- **Eribulin as a single agent or in combination - 10**
- **Everolimus + Exemestane - <5**
- **Fulvestrant as a single agent - 54**
- **Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) - <5**
- **Palbociclib + Fulvestrant - 22**
- **Parp Inhibitors (Olaparib/Talazoparib) - <5**
- **Pembrolizumab - <5**
- **Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) - <5**
- **Ribociclib + Fulvestrant - 10**
- **Sacituzumab Govitecan - 7**
- **Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent - 42**
- **Transtuzumab deruxtecan - 32**
- **Trastuzumab as a single agent or in combination - <5**
- **Trastuzumab emtansine - 42**
- **Any other active systemic anti-cancer therapy**

**Abemaciclib - 94**

**AC - <5**

**Accelerate EC - <5**

**Alpelisib & Fulvestrant - 5**

**Atezolizumab & Nab-Paclitaxel - <5**

**29 October 2024**

**Carboplatin AUC 6 - <5**

**D-Carbo-Phesgo - 24**

**EC-100 - <5**

**EC-50 - <5**

**EC-D - 52**

**EC-D-Phesgo - 45**

**ED-PC - 16**

**EC-Weekly Paclitaxel - 17**

**EC-Wkly Paclitaxel-Phesgo - 7**

**Epirubicin - <5**

**FEC - 8**

**FEC-D - <5**

**FEC-D & Herceptin - <5**

**FEC-D & Phesgo - 9**

**FEC Wkly Paclitaxel Phesgo - <5**

**Goserelin - 26**

**Herceptin - 29**

**Neratinib - 5**

**Paclitaxel wkly - 28**

**Palbociclib - 87**

**Pembro+Paclitaxel - <5**

**Penbrolizumab + PC-EC - 13**

**Ribociclib - 51**

**Tucatinib Capecitabine Trastuzumab - 6**

**Vinorelbine - 9**

29 October 2024

Wkly Paclitaxel Phesgo - 9

Zoledronic Acid – 31

**Q2. Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.**

**Open Breast Cancer Trials**

Short title	Full title	Number of patients recruited
<b>OPTIMA</b>	OPTIMA Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis	52
<b>SMALL</b>	A Phase III, randomised, multi-centre trial addressing overtreatment of small, screen-detected breast cancer by comparing standard surgery with minimally invasive vacuum-assisted excision	33
<b>ATNEC</b>	Axillary management in T1-3N1M0 breast cancer patients with needle biopsy proven nodal metastases at presentation after neoadjuvant chemotherapy	5
<b>EndoNET</b>	Randomised controlled trial evaluating effectiveness of neoadjuvant endocrine therapy in post-menopausal women	<5
<b>HER2-RADiCAL</b>	The HER2-RADiCAL study (Response Adaptive Care pLan) - Tailoring treatment for HER2 positive early breast cancer	<5
<b>POETIC-A</b>	PreOperative Endocrine Therapy for Individualised Care with Abemaciclib	<5 (12 registered to screening)

**Trials in Set-up**

<b>WO44263 (INAVO122)</b>	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination with Phesgo Versus Placebo in Combination with Phesgo After First Line Induction Therapy in Participants with <i>PIK3CA</i> -Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
<b>LION</b>	Pan Tumour Trial of Cox-Inhibitor and Immune Checkpoint Blockade

**29 October 2024**

<b>BLUSH</b>	OxyButynin or venlafaxine for hot flushes in women who cannot or chose not to use hormone replacement therapy: randomised trial and economic evaluation
<b>Lolipop</b>	Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain
<b>ADELA</b>	A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors.

Where numbers are low we have indicated <5 rather than give the exact figure. We feel that providing the exact figure has the potential to make people identifiable and so that information is exempt from release under Section 40(2) of the Freedom of Information Act 2000.